Global Human Milk Oligosaccharides (HMOs) in Infant Formula Market – Industry Trends and Forecast to 2030

Global Human Milk Oligosaccharides (HMOs) in Infant Formula Market, By Type (2’FL, 3’FL, 3’SL and 6’SL), Concentration (Neutral, Acidic), Applications (Infant Formulas, Health Ingredients for Human and Animal, Food and Beverages and Food Supplements), Distribution channel (Hypermarkets and Supermarkets, Drug Store or Pharmacy, Mass Merchandiser, Departmental Stores, Mono-brand Stores, Specialty Stores, Online Sales Channel) – Industry Trends and Forecast to 2030.

Human Milk Oligosaccharides (HMOs) in Infant Formula Market Analysis and Size

Human milk oligosaccharides (HMOs) are a gut-strengthening vitamins that have been scientifically proven to support immunity and digestion in infant. In past years, with increasing consumer inclination toward gut health, it has grown into a problem for various people all over the globe. Thus, 75 percent of consumers like to eat food that promotes a healthy microbiome, and 56% like products that support them to digest better. As a result, the demand for human milk oligosaccharides in preparing infant formulas is due to qualities such as infection prevention, gut health maintenance, prebiotic effects, memory improvement and brain growth.

Data Bridge Market Research analyses that the human milk oligosaccharides (HMOs) in infant formula market is expected to reach USD 540.12 billion by 2030, which is USD 115.24 billion in 2022, registering a CAGR of 21.30% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.     

Human Milk Oligosaccharides (HMOs) in Infant Formula Market Scope and Segmentation

Market Definition

Human milk oligosaccharides (HMOs) are indigestible sugars which found in human milk. HMOs help to increase the immune system's development and can block pathogen infections. It also improves brain development and gut bacteria. These indigestible sugars are breast milk's third most important element after lipids and lactose.

Human Milk Oligosaccharides (HMOs) in Infant Formula Market Dynamics

Drivers

• Multiple benefits associated with human milk oligosaccharides

Human milk oligosaccharides (HMOs) are gaining high popularity for infant growth owing to the potential benefits associated with their consumption, such as providing HMOs as a prebiotic to help in maintaining a healthy immune system in infants. It also aids to improving gut colonization and also prevent foreign particles and microbial pathogens from adhering to epithelial surfaces. Human milk oligosaccharides is a healthier option for non-lactating mothers because it comprises all nutrients required for infants' normal growth. Therefore, as a result of many benefits of human milk oligosaccharides is expected to drive the market growth.

• Growing acceptance of human milk oligosaccharides

Human milk oligosaccharides are major components of human milk and used in numerous concentrations and compositions. In the regulatory sense, HMOs are new ingredients or food that need safety assessment. In the U.S., the human milk oligosaccharides intended for use in food other than. In U.S CARE4U was approved for use in toddler foods and infant formula. Therefore, growing acceptance of human milk oligosaccharides will drive the market growth.

Opportunities

• Increasing investment in R&D activities by market participants

The major market players have invested in research and development activities to update their product offerings. For instance, in 2019, Jennewein Biotechnologie GmbH, a functional sugars manufacturer based in Germany, collaborated with Yili. Inc., a dairy products manufacturer based in China, to conduct research on human milk oligosaccharides and infant microbiome. This strategy was planned to create innovative, human milk oligosaccharides (HMOs) in infant formula for Chinese customers. Thus, increasing investment in R&D activities by market participants will create lucrative opportunities for market growth.

• Rising acquisition between market players for accelerate the growth of HMO product

Growing adoption of agreement and strategic partnership among major players is expected to create lucrative growth opportunities. For instance, Royal DSM has acquired Glycom which is one of the major suppliers of Human Milk Oligosaccharides (HMO) for an enterprise value of USD 765 million in 2021. With this acquisition, DSM could surge the growth of Glycom by providing HMO products under the "Early Life Nutrition" segment. This will help to accelerate the HMO product development of Glycom by leveraging its R&D platform to support Glycom's development of next-generation HMOs.

Restraints/ Challenges

• Rising government initiatives to boost breastfeeding over formula

Rising government initiatives to boost breastfeeding over formula feeding is anticipated to hamper the market growth. The American Academy of Pediatrics and U.S. Dietary Guidelines for Americans recommend exclusive breastfeeding alert icons for around six months and then continuing breastfeeding while introducing other foods alert icons until the child is 12 months old or older. Also, the natural breastfeeding HMOs supports growth and development more than the artificial synthesized HMOs, which will hamper the market growth.

This human milk oligosaccharides (HMOs) in infant formula market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human milk oligosaccharides (HMOs) in infant formula market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Impact and Current Market Scenario of Raw Material Shortage and Shipping Delays

Data Bridge Market Research offers a high-level analysis of the market and delivers information by keeping in account the impact and current market environment of raw material shortage and shipping delays. This translates into assessing strategic possibilities, creating effective action plans, and assisting businesses in making important decisions.

Apart from the standard report, we also offer in-depth analysis of the procurement level from forecasted shipping delays, distributor mapping by region, commodity analysis, production analysis, price mapping trends, sourcing, category performance analysis, supply chain risk management solutions, advanced benchmarking, and other services for procurement and strategic support.

Expected Impact of Economic Slowdown on the Pricing and Availability of Products

When economic activity slows, industries begin to suffer. The forecasted effects of the economic downturn on the pricing and accessibility of the products are taken into account in the market insight reports and intelligence services provided by DBMR. With this, our clients can typically keep one step ahead of their competitors, project their sales and revenue, and estimate their profit and loss expenditures.

Recent Development

• In 2021, H&H Group revealed its first toddlers supplement that contains Human Milk Oligosaccharides (HMOs). This product is called as ProBOOST + Vit D which comes under the brand name Biostime. This product can be consumed by kids aged 12 months and above this.
• In 2020, Kyowa Hakko developed a new capability to form human milk oligosaccharides (HMOs) in Thailand, owing to the increasing demand for these health products worldwide in the upcoming period.
• In 2021, Chr Hansen signed a contract with Jennewein Biotechnologie to acquire its complete stake in EUR 310 million deal. Jennewein is involved in the making of human milk oligosaccharides and rare monosaccharides such as Sialic acid and L-Fucose.
• In 2021, BASF announced that PREBILAC, the BASF’s brand of 2’-FL, had received authorization from Australia’s Therapeutic Goods Administration. This is making it the first and only 2’-FL ingredient to receive approval of TGA as a prebiotic ingredient.

 Global Human Milk Oligosaccharides (HMOs) in Infant Formula Market Scope

The human milk oligosaccharides (HMOs) in infant formula market is segmented on the basis of type, concentration, applications and distribution channel t. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 2’FL
• 3’FL
• 3’SL
• 6’SL

Concentration

• Neutral
• Acidic

 Applications

• Infant Formulas
• Health Ingredients for Human and Animal
• Food and Beverages
• Food Supplements

Distribution channel

• Hypermarkets and Supermarkets
• Drug Store or Pharmacy
• Mass Merchandiser
• Departmental Stores
• Mono-brand Stores
• Specialty Stores
• Online Sales Channel

 Human Milk Oligosaccharides (HMOs) in Infant Formula Market Regional Analysis/Insights

The human milk oligosaccharides (HMOs) in infant formula market is analyzed and market size insights and trends are provided by country type, concentration, applications and distribution channel as referenced above.

The countries covered in the human milk oligosaccharides (HMOs) in infant formula market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Asia-Pacific dominates the human milk oligosaccharides (HMOs) in infant formula market in terms of revenue and market share owing to the availability of a huge customer base for human milk oligosaccharides (HMOs) derivative products in this region. Also, since the region of Asia-Pacific is highly populated by countries such as China and India, it witnesses a large growth in infant population every year which also positively influence the market growth.

North America is expected to be the fastest developing region during the forecast period of 2023-2030 due to increasing disposable income and rising concerns regarding gut diseases, diabetes, and high blood pressure in this region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Human Milk Oligosaccharides (HMOs) in Infant Formula Market Share Analysis

The human milk oligosaccharides (HMOs) in infant formula market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human milk oligosaccharides (HMOs) in infant formula market.

Some of the major players operating in the human milk oligosaccharides (HMOs) in infant formula market are:

• ZuChem Inc. (U.S.)
• Elicityl SA (France)
• Jennewein Biotechnologie GmbH (Germany)
• Friesland Campina (Netherlands)
• BASF SE (Germany)
• Gnubiotics (Switzerland)
• Inbiose NV (Belgium)
• Glycom A/S (Denmark)
• Glycosyn LLC (U.S.)
• Nestle S.A. (Switzerland)
• DuPont (U.S.)
• DSM (Netherlands)
• Chr. Hansen A/S (Denmark)
• Biosynth Carbosynth (Switzerland)
• Flavors & Fragrances Inc. (U.S.)
• Abbott (U.S.)
• Medolac (U.S.)